HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Triclosan

This article was originally published in The Rose Sheet

Executive Summary

Consumers should refrain from using soap and other products containing triclosan and other biocides at home, according to the Federal Institute for Risk Assessment, a new scientific body of the Federal Republic of Germany. Noting consumer products contain only low doses of triclosan insufficient to kill bacterial pathogens, FIRA adds, "When it comes to everyday life, soap and water or conventional cleansing products are quite capable of achieving the same effect." The institute expressed concern over the risk of increasing resistance of microorganisms to the ingredient, and concluded products containing triclosan should only be used in clinics and doctors' offices. Antibacterial resistance associated with triclosan use has been a topic of increasing interest in the U.S. In October, FDA's Nonprescription Drugs Advisory Committee unanimously agreed that makers of non-alcohol-based antimicrobials should be required to demonstrate products' clinical benefit prior to sale (1"The Rose Sheet" Oct. 24, 2005, p. 9)...

You may also be interested in...



Non-Alcohol Antiseptic Hand Products Should Prove Efficacy – NDAC

Marketers of non-alcohol-based consumer antiseptic products should be required to prove their products provide clinical benefit prior to sale, an FDA advisory panel unanimously agreed Oct. 20

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014052

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel